iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases... Show more
iBio, Inc. has repositioned itself as a clinical-stage biotechnology company pairing AI-driven discovery with advanced antibody engineering to develop long-acting therapeutics for obesity, cardiometabolic disease, and cardiopulmonary conditions. Rather than competing head-on with the leading incretin-based obesity drugs, iBio is building what it describes as complementary assets — antibodies engineered to preserve or build muscle and selectively reduce fat, areas of significant unmet need as GLP-1 therapies expand.
The company's differentiation rests on two pillars: a computational and 3D-modeling discovery platform that aims to accelerate development timelines, and a portfolio engineered for infrequent dosing. IBIO-610, for instance, is being developed with a potentially extended human half-life that management suggests could support dosing as infrequently as twice per year. This focus on durability and muscle preservation could position iBio favorably within a maturing obesity-treatment ecosystem, though it remains a preclinical-to-early-clinical company whose commercial validation is still years away.
The most consequential near-term catalyst is the initiation and progression of the IBIO-600 Phase 1 trial, which received regulatory and ethics clearance in Australia in April 2026 with first dosing targeted for the second quarter of 2026. Early safety, tolerability, and pharmacokinetic data will offer the first clinical read on whether the antibody can deliver on its muscle-preservation thesis.
Looking further out, iBio is guiding toward first-in-human studies for IBIO-610 in early calendar year 2027, a milestone that could meaningfully expand the narrative from a single-asset story to a multi-asset pipeline. The advancement of IBIO-800 into investigational new drug (IND)-enabling development and continued characterization of the in-licensed amylin receptor antibody program add additional layers of optionality.
Analyst sentiment has remained broadly constructive even as the stock has re-rated lower. Multiple firms — including H.C. Wainwright, B. Riley, Leerink Partners, Raymond James, and Oppenheimer — initiated or reiterated Buy or Outperform ratings through 2026, with consensus carrying a "Strong Buy" profile and an average price target in the $5.53 to $5.69 range. These figures represent external expectations about pipeline value rather than near-term earnings power, and they underscore a consensus that skews optimistic about the company's clinical trajectory.
iBio's future is closely tied to the commercial momentum of the broader obesity and cardiometabolic market, where investor enthusiasm for GLP-1 therapies and their combination partners remains elevated. Any shift in how regulators, payers, or clinicians value muscle-preservation and body-composition endpoints could directly influence demand for iBio's differentiated approach.
At the macro level, clinical-stage biotech remains sensitive to the interest-rate environment and risk appetite. Higher-for-longer rates tend to compress valuations of pre-revenue companies with distant cash flows, while easing conditions can support capital formation and financing. Inflation in clinical development costs and competition for specialized talent also influence the pace at which iBio can advance its pipeline. Finally, regulatory clarity around weight-loss endpoints and long-term safety will be a key determinant of the company's long-term addressable market.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the coming week or month. The tool is built to surface developing trends, evaluate potential breakouts or reversals, and allow users to explore predictions across a wide range of tradable instruments. It also provides searchable prediction categories, historical context, and alert-oriented functionality to support more informed decision-making. For investors tracking iBio's evolving story, tools like this can offer an additional, data-driven lens alongside fundamental analysis.
Into 2026 and beyond, iBio's trajectory hinges on its ability to convert a promising preclinical platform into credible clinical data. The company's strategic priority is clear: advance IBIO-600 through early-stage trials, move IBIO-610 toward the clinic in early 2027, and continue developing the bispecific and amylin programs. Success on these fronts could establish iBio as a differentiated player in the muscle-preservation and fat-selective weight-loss space, where combination strategies with GLP-1 therapies are attracting growing interest.
Longer-term themes include the evolution of cost structure as R&D spending scales, the sustainability of the company's cash runway into fiscal 2028, and the competitive threat from larger pharmaceutical companies pursuing similar biology. Capital allocation priorities — including the open market sale agreement of up to $100 million and potential future financings — will also shape dilution and investor sentiment. Regulatory developments around obesity endpoints and any partnership activity remain important swing factors. External consensus expectations, reflected in a "Strong Buy" rating and average price targets near $5.69, signal that many analysts see substantial optionality, but these targets are forward-looking estimates rather than guarantees of future performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GJS | 23.49 | N/A | N/A |
| Synthetic Fixed-Income Securities STRATS 2006-2 Goldman Sachs Group | |||
| BKWO | 37.72 | N/A | N/A |
| BNY Mellon Womens's Opportunities ETF | |||
| PAUG | 45.76 | -0.25 | -0.54% |
| Innovator U.S. Equity Power Buffer ETF - August (PAUG) | |||
| JANW | 39.13 | -0.24 | -0.61% |
| AllianzIM U.S. Equity Buffer20 Jan ETF (JANW) | |||
| KAUG | 27.80 | -0.23 | -0.80% |
| Innovator US Small Cap Power Buffer ETF - August (KAUG) | |||
A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with WVE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then WVE could also see price increases.
| Ticker / NAME | Correlation To IBIO | 1D Price Change % | ||
|---|---|---|---|---|
| IBIO | 100% | +5.86% | ||
| WVE - IBIO | 47% Loosely correlated | -1.05% | ||
| GPCR - IBIO | 39% Loosely correlated | -2.15% | ||
| REPL - IBIO | 38% Loosely correlated | -8.03% | ||
| EDIT - IBIO | 38% Loosely correlated | -2.41% | ||
| KYMR - IBIO | 37% Loosely correlated | -3.44% | ||
More | ||||
a company which engages in the development and commercialization of vaccines and therapeutic proteins
Industry Biotechnology
The Moving Average Convergence Divergence (MACD) for IBIO turned positive on October 27, 2026. Looking at past instances where IBIO's MACD turned positive, the stock continued to rise in 36 of 39 cases over the following month. The odds of a continued upward trend are 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IBIO's RSI Oscillator exited the oversold zone, 32 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +8.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBIO advanced for three days, in 186 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBIO as a result. In 71 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for IBIO entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.554) is normal, around the industry mean (3.592). P/E Ratio (-2.308) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. IBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.